Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Target Cut by Royal Bank Of Canada

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target lowered by investment analysts at Royal Bank Of Canada to $1.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has a “sector perform” rating on the stock. Royal Bank Of Canada‘s target price points to a potential upside of 146.79% from the stock’s current price.

Several other analysts have also commented on EYPT. Cantor Fitzgerald lowered Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Monday, August 17th. Jefferies Financial Group lowered Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 price objective for the company. in a report on Monday. Guggenheim lowered Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday. TD Cowen lowered Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price objective for the company from $20.00 to $4.00 in a report on Wednesday, September 2nd. Finally, Citigroup decreased their price objective on Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating for the company in a report on Tuesday, August 18th. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $21.85.

Eyepoint Pharmaceuticals Stock Performance

Eyepoint Pharmaceuticals stock traded down $0.03 during mid-day trading on Tuesday, reaching $0.41. 50,861,366 shares of the company were exchanged, compared to its average volume of 3,295,775. The business has a fifty day moving average of $4.77 and a 200 day moving average of $10.30. The firm has a market cap of $34.93 million, a P/E ratio of -0.11 and a beta of 1.67. Eyepoint Pharmaceuticals has a 12-month low of $0.40 and a 12-month high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The business had revenue of $0.51 million for the quarter, compared to analysts’ expectations of $0.45 million. Sell-side analysts predict that Eyepoint Pharmaceuticals will post -3.51 EPS for the current year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its stake in Eyepoint Pharmaceuticals by 22.6% in the 1st quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock worth $46,419,000 after acquiring an additional 663,439 shares during the last quarter. Commodore Capital LP purchased a new position in Eyepoint Pharmaceuticals in the 1st quarter worth $36,414,000. Hsbc Holdings PLC purchased a new position in Eyepoint Pharmaceuticals in the 1st quarter worth $10,743,000. Stempoint Capital LP grew its position in Eyepoint Pharmaceuticals by 129.1% during the 1st quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock worth $10,451,000 after purchasing an additional 456,915 shares during the period. Finally, Principia Wealth Advisory LLC grew its position in Eyepoint Pharmaceuticals by 2.6% during the 2nd quarter. Principia Wealth Advisory LLC now owns 649,944 shares of the company’s stock worth $9,294,000 after purchasing an additional 16,180 shares during the period. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Key Stories Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: EyePoint is prioritizing its late-stage DURAVYU DME program, which could become the company’s primary value driver after the wAMD setback. RBC identified the upcoming DME study readout as a possible catalyst. EyePoint’s DME Study Readout a Catalyst After wAMD Trial Misses Endpoint, RBC Says
• Positive Sentiment: Analysts’ price targets of $1.00 from Royal Bank of Canada and Jefferies imply substantial potential upside from the current depressed valuation, although both firms are no longer bullishly rated. RBC Price Target Update
• Neutral Sentiment: RBC moved to “sector perform” with a $1.00 target, while Laidlaw reaffirmed “hold,” HC Wainwright and Mizuho maintained “neutral,” and JPMorgan reaffirmed “underweight.” Mizuho set a $0.50 target.
• Neutral Sentiment: Unusually heavy call-option activity was reported, with investors purchasing 7,885 calls—69% above typical volume—suggesting speculative interest but not confirming a fundamental turnaround.
• Negative Sentiment: The Phase 3 LUCIA trial of DURAVYU in wAMD failed to meet its primary endpoint, prompting EyePoint to halt related clinical trials and sharply reduce expenses. EyePoint Announces LUCIA Topline Results
• Negative Sentiment: EyePoint plans to cut approximately 53% of its workforce and pivot resources toward DME, underscoring the seriousness of the trial failure and the company’s need to preserve cash. EyePoint Announces Strategic Prioritization
• Negative Sentiment: Guggenheim downgraded the shares to “neutral,” while Jefferies cut its rating from “buy” to “hold.” A shareholder-investigation notice from Levi & Korsinsky adds further headline and legal risk. EyePoint Pharmaceuticals Investigation Notice

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.